Skip to main content

Table 1 Baseline characteristics of eligible studies in the meta-analyses

From: Hypertension as a prognostic factor in metastatic renal cell carcinoma treated with tyrosine kinase inhibitors: a systematic review and meta-analysis

Study

Year

Country

Study design

Sample size

Male/ Female ratio

Mean age

Histology (clear cell%)

Survival analysis

Definition of hypertension

Type of analysis

TKIs

Quality Assessment (NOS Score = 9)

Rini (a) [10]

2011

the USA

R

534

2.3

60.6

98%

PFS, OS

SBP ≥ 140 mmHg, DBP ≥ 90 mmHg

multivariate

SUN

7

Szmit [12]

2011

Poland

R

111

3.0

55.9

100%

PFS, OS

BP ≥ 140/90 mmHg

univariate

SUN

9

Bono [17]

2011

Finland

R

64

1.7

64

92%

PFS

BP > 150/100 mmHg OR blood pressure requiring intensifi cation of pre-existing anti-hypertensive medication.

multivariate

SUN

7

Fujita [18]

2012

Japan

R

41

2.7

64

100%

PFS

univariate

SUN

7

Eechoute [19]

2012

Netherlands

R

158

1.7

60

87%

PFS, OS

SBP > 140 mmHg, DBP > 90 mmHg, MAP > 110 mmHg

multivariate

SUN

7

Rini (b) [13]

2013

the USA

R

168

2.5

60

PFS, OS

DBP ≥90 mmHg

multivariate

AXI

7

Motzer (a) [20]

2013

the USA

P

350

2.8

61

100%

PFS, OS

SBP > 140 mmHg, DBP > 90 mmHg

multivariate

AXI

6

Motzer (b) [20]

2013

the USA

P

336

2.5

61

100%

PFS, OS

SBP > 140 mmHg, DBP > 90 mmHg

multivariate

SOR

6

Hong [21]

2013

China

R

136

2.0

56

93%

OS

Hypertension class III/IV

multivariate

SUN

7

Nakano [22]

2013

Japan

R

36

3.5

65.8

61%

PFS

grade 1–3 (NCI-CTCAE, version 3.0)

multivariate

SOR

7

Fujita [23]

2014

Japan

R

44

2.7

63.5

95%

PFS

multivariate

SUN

7

Eto [24]

2014

Japan

R

64

2.2

63

97%

OS

DBP ≥90 mmHg

AXI

7

Rini (c) [25]

2015

the USA

P

203

2.0

61.9

PFS

DBP change from baseline ≥10/15 mmHg

AXI

7

Zhang (a) [26]

2015

China

R

256

2.5

58

79%

OS

multivariate

SOR

7

Kucharz [27]

2015

Poland

R

28

2.1

65

PFS

office SBP ≥140 and/or DBP ≥90 mmHg; home SBP ≥135 and/or DPB ≥85 mmHg; pre-existing medication-controlled arterial hypertension and required additional antihypertensive medication during treatment

multivariate

SUN

7

Izzedine [28]

2015

France

R

212

3.4

57.7

86%

PFS, OS

multivariate

SUN

8

Donskov [29]

2015

the USA

R

770

2.6

60

98%

PFS

SBP ≥ 140 mmHg

multivariate

SUN

7

Zhang (b) [30]

2016

China

R

134

2.4

59.8

77%

OS

multivariate

SOR

7

Goldstein (a) [14]

2016

Australia

R

479

2.2

59.5

PFS, OS

MAP change from baseline>10 mmHg

univariate

PAZ

9

Goldstein (b) [14]

2016

Australia

R

506

2.6187

61

PFS, OS

SBP > 140 mm H, DBP > 90 mmHg, MAP change from baseline>10 mmHg, SBP change from baseline>10 mmHg

univariate

PAZ

9

Goldstein (c) [14]

2016

Australia

R

475

3.3394

60.9

PFS, OS

SBP > 140 mm H, DBP > 90 mmHg, MAP change from baseline>10 mmHg, SBP change from baseline>10 mmHg

univariate

SUN

9

Cecere [31]

2016

Italy

R

38

1.375

61

84.2%

OS

grade ≥ 3 (NCI-CTCAE, version 4.0)

multivariate

PAZ

7

Miyake [32]

2016

Japan

R

50

4.0000

64

80%

PFS

SBP ≥ 140 or DBP ≥ 90 mmHg

multivariate

SUN

7

Fukuda [15]

2016

Japan

R

62

2.4444

66

92%

PFS, OS

univariate

SUN

7

Matias [33]

2017

France

P

106

2.3125

54

90%

PFS, OS

grade ≥ 3 (NCI-CTCAE, version 4.0)

univariate

AXI

7

  1. R Retrospective, P Prospective, PFS Progression-free survival, OS Overall survival, SBP Systolic blood pressure, DBP Diastolic blood pressure, MAP ≈ 2/3 DBP + 1/3 SBP; SUN Sunitinib, AXI Axitinib, SOR Sorafenib, PAZ Pazopanib, NCI-CTCAE National Cancer Institute Common Terminology Criteria for Adverse Events
  2. —: The data were not available in this study